Price T Rowe Associates Inc Century Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 14,882 shares of IPSC stock, worth $23,811. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,882Holding current value
$23,811% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IPSC
# of Institutions
61Shares Held
35MCall Options Held
7KPut Options Held
300-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$8.66 Million2.82% of portfolio
-
Vr Adviser, LLC New York, NY5.39MShares$8.62 Million1.51% of portfolio
-
Boxer Capital, LLC San Diego, CA4.9MShares$7.84 Million0.69% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$5.13 Million0.71% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$4.63 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $94.2M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...